# CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC

> **NCT07449065** · — · COMPLETED · sponsor: **First Affiliated Hospital, Sun Yat-Sen University** · enrollment: 324 (actual)

## Conditions studied

- Hepatocellular Carcinoma (HCC)
- Transarterial Chemoembolization
- Microvascular Invasion (MVI)
- Tyrosine Kinase Inhibitors

## Interventions

- **DRUG:** TKI
- **PROCEDURE:** TACE

## Key facts

- **NCT ID:** NCT07449065
- **Lead sponsor:** First Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-01
- **Primary completion:** 2025-10-31
- **Final completion:** 2025-10-31
- **Target enrollment:** 324 (ACTUAL)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07449065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07449065, "CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07449065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*